Ceftazidime

Overview

Ceftazidime (Ceptaz®, Fortaz®, Tazicef®) is a third-generation cephalosporin administered parenterally and used in dogs and cats primarily for serious gram-negative infections, particularly those caused by Pseudomonas spp. It is generally reserved for severe systemic infections when safer or labeled veterinary alternatives are not appropriate.

Unlike most other third-generation cephalosporins, ceftazidime has true anti-pseudomonal activity. It is bactericidal and time-dependent, requiring adequate and sustained plasma concentrations to maintain efficacy. In severe systemic Pseudomonas aeruginosa infections, frequent dosing or constant rate infusion (CRI) may be necessary.

Mechanism of Action (MOA): Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to disruption of cell wall integrity and bacterial death. It retains activity against many gram-negative organisms but is ineffective against methicillin-resistant staphylococci, enterococci, and ESBL-producing bacteria.

Indications

Ceftazidime is used in dogs and cats primarily for serious, culture-confirmed gram-negative infections, especially when Pseudomonas spp. are suspected or documented. Because it is a critically important antimicrobial in human medicine, its use should be reserved for cases where first-line or labeled veterinary alternatives are not appropriate or effective.

• Serious systemic gram-negative infections: Including septicemia, pneumonia, deep tissue infections, and other severe infections caused by susceptible organisms.
• Pseudomonas aeruginosa infections: Particularly valuable in infections where anti-pseudomonal activity is required and other options (eg, aminoglycosides) are contraindicated or carry unacceptable toxicity risks.
• Complicated urinary tract infections: When caused by susceptible gram-negative bacteria and confirmed by culture and susceptibility testing.
• Central nervous system infections: As it penetrates inflamed meninges and may be considered when culture results support its use.
• Bone and joint infections: Due to its distribution into bone, when susceptible gram-negative organisms are involved.

Because bacterial susceptibility to third-generation cephalosporins varies between agents, ceftazidime-specific susceptibility testing should be performed before initiating therapy whenever possible.

Dosage (Reference)

Dog

In dogs, dosing frequency may need to be increased in serious infections, especially those caused by Pseudomonas aeruginosa, because ceftazidime has a relatively short elimination half-life.

Cat

In cats, dosing may need to be intensified when treating infections caused by Pseudomonas spp. due to the time-dependent nature of ceftazidime.

Warnings & Precautions

Ceftazidime should be reserved for serious infections in dogs and cats, particularly those caused by susceptible gram-negative organisms such as Pseudomonas spp. Careful patient selection and monitoring are required due to renal elimination and the potential for neurologic toxicity in compromised patients.

• Hypersensitivity: Contraindicated in patients with a known allergy to cephalosporins. Use cautiously in animals with documented hypersensitivity to other beta-lactam antibiotics (eg, penicillins, carbapenems) due to possible cross-reactivity.
• Renal insufficiency: Primarily excreted unchanged by the kidneys. Accumulation may occur in patients with markedly impaired renal function; dosage interval adjustment may be necessary.
• Risk of neurotoxicity: Seizures, myoclonus, or encephalopathy may occur, particularly in patients with renal impairment or drug accumulation.
• Injection site reactions: IM administration may cause pain; SC administration may be less painful but local reactions are possible.
• Use in pregnancy and lactation: Cephalosporins cross the placenta. Although teratogenic effects have not been demonstrated in laboratory studies, safety in dogs and cats has not been definitively established. Use only when maternal benefit outweighs potential risk to offspring.
• Antimicrobial stewardship: Because ceftazidime is considered critically important in human medicine, its use should be guided by culture and susceptibility testing whenever possible.
• Medication errors: Ceftazidime can be confused with other cephalosporins; clear prescription labeling (eg, tall-man lettering such as cefTAZidime) is recommended to reduce dispensing errors.

Drug Interactions

The following drug interactions have been reported or are theoretical in dogs and cats receiving ceftazidime. Concurrent use is not always contraindicated, but potential risks should be evaluated and appropriate monitoring performed.

• Aminoglycosides (eg, amikacin, gentamicin): Potential for additive nephrotoxicity when used concurrently. Although synergistic antibacterial activity may occur against certain gram-negative organisms, these drugs should be administered separately and renal function should be monitored closely.
• Other nephrotoxic drugs (eg, amphotericin B, furosemide, iohexol): Concurrent use may increase the risk of renal injury. Monitor renal parameters (BUN, creatinine, urinalysis) during combined therapy.
• Chloramphenicol: May antagonize the bactericidal activity of ceftazidime against gram-negative bacilli; concurrent use is not recommended.
• Vitamin K antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect, potentially increasing the risk of bleeding.

When combining ceftazidime with other medications, especially nephrotoxic agents, careful monitoring of renal function and clinical response is advised.

Side Effects & Overdose

Side Effects

Because veterinary use of ceftazidime has been limited, a complete adverse effect profile in dogs and cats has not been fully established. Reported and potential adverse effects are generally consistent with other cephalosporins.

• Gastrointestinal signs: Diarrhea and other GI disturbances have been reported in dogs after SC administration.
• Injection site reactions: Pain may occur with IM administration; SC injection may also cause discomfort or local irritation.
• Hypersensitivity reactions: Allergic reactions may occur and can range from mild skin reactions to more severe responses.
• Hematologic effects: Although primarily reported in humans, hemolytic anemia and other blood dyscrasias are possible with cephalosporins.
• Hepatic enzyme elevations: Increases in serum liver enzymes (eg, ALT, AST, LDH, GGT) have been described in human patients; clinical relevance in dogs and cats is unknown.
• Pseudomembranous colitis: Overgrowth of Clostridium difficile may occur with antibiotic use.

Overdose

Acute overdose in patients with normal renal function is unlikely to cause severe toxicity. However, in patients with renal insufficiency, drug accumulation can increase the risk of neurologic complications.

• Neurologic toxicity: Seizures, myoclonus, encephalopathy, coma, neuromuscular excitability, and asterixis may occur, particularly in patients with impaired renal function.
• Management: Treatment is primarily supportive and based on clinical signs.
• Enhanced elimination: Hemodialysis may be considered to enhance elimination in severe cases; ceftazidime is significantly cleared during continuous renal replacement therapies.

Key Notes

Additional practical considerations for the clinical use of ceftazidime in dogs and cats:

• Time-dependent killing: Clinical success depends on maintaining drug concentrations above the organism’s MIC for an adequate portion of the dosing interval; missed doses can significantly reduce efficacy.
• Short half-life: Because elimination is rapid in both dogs and cats, strict adherence to dosing intervals is critical for serious systemic infections.
• Culture-driven therapy: Empirical use should be limited; therapy should ideally be guided by culture and ceftazidime-specific susceptibility testing.
• Gram-negative focus: Most appropriate when gram-negative pathogens are strongly suspected or confirmed, particularly in hospital-acquired infections.
• CSF and bone penetration: Distribution into cerebrospinal fluid (when meninges are inflamed) and bone may make it useful in selected severe infections at these sites.
• Client compliance consideration: Because the drug requires injection and frequent dosing in many cases, ensure owners understand the administration schedule before initiating outpatient therapy.
• Monitor high-risk patients: Dogs and cats receiving prolonged therapy or intensive dosing should have periodic clinical reassessment and laboratory monitoring.